
About
Physical Characteristics
Caps:
De tamaño mediano a grande con forma cónica, inicialmente de color marrón caramelo y volviéndose marrón claro con la edad.
Gills:
Inicialmente grisáceo, madurando a un marrón púrpura oscuro
Cognitive Effects
Creatividad
Muchas personas informan de una mayor creatividad y una sensación de fluidez ideacional aumentada bajo la influencia de la psilocibina. Esto puede incluir habilidades mejoradas para resolver problemas, ideas novedosas y pensamiento innovador.
Psychoactive Effects
AlucinóGeno
Induce alucinaciones, alterando la percepción de la realidad.
EufóRico
Produce intensos sentimientos de felicidad o emoción.
Helps With
Depresión
Puede aliviar los síntomas de la depresión.
Ansiedad
Puede ayudar a reducir los síntomas de ansiedad.
TEPT
Puede ayudar a aliviar los síntomas del TEPT.
Adicción
Puede ayudar a reducir comportamientos adictivos.
TOC
Puede ayudar a reducir los síntomas del TOC.
Dolor
El microdosing de psilocibina ha demostrado ayudar con ciertos tipos de dolor.
Migrañas
La investigación muestra que la psilocibina, el compuesto activo en los hongos alucinógenos, tiene potenciales beneficios terapéuticos para las migrañas. Un estudio a pequeña escala realizado por la Escuela de Medicina de Yale encontró que una sola dosis de psilocibina redujo la probabilidad de tener un ataque de migraña en dos semanas.
Possible Side Effects
Náusea
Puede causar malestar estomacal o sensación de estar enfermo.
Paranoia
Puede causar sentimientos excesivos de miedo o angustia.
Parálisis de los amantes de la madera
Cuando se consume en grandes cantidades, puede causar parálisis temporal.
Medicinal Chemistry
Similar Species

Species: Psilocybe Cyanescens
Edibility: Psicoactivo
Key Differences: Psilocybe Cyanescens tiene un sombrero más ondulado en comparación con el sombrero convexo a subumbonado de Psilocybe Azurescens.

Species: Psilocybe Cyanescens
Edibility: Psicoactivo
Mushroom Ratings
0.0
Based on 0 Reviews
5
★4
★3
★2
★1
★Share your thoughts
If you've consumed this mushroom, share your thoughts with our community
References
Psilocybin desynchronizes the human brain
Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?
Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants
Cardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis
Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial
Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation
Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users—A National Survey Study
Psilocybin: From Serendipity to Credibility?
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain
Healthy adults were tracked before, during and for 3 weeks after high-dose psilocybin (25 mg) and methylphenidate (40 mg), and brought back for an additional psilocybin dose 6–12 months later. Psilocybin massively disrupted functional connectivity (FC) in cortex and subcortex, acutely causing more than threefold greater change than methylphenidate. These FC changes were driven by brain desynchronization across spatial scales (areal, global), which dissolved network distinctions by reducing correlations within and anticorrelations between networks. Psilocybin-driven FC changes were strongest in the default mode network, which is connected to the anterior hippocampus and is thought to create our sense of space, time and self.
2024
Major depressive disorder (MDD) is one of the most disabling psychiatric disorders in the world. First-line treatments such as selective serotonin reuptake inhibitors (SSRIs) still have many limitations, including a resistance to treatment in 30% of patients and a delayed clinical benefit that is observed only after several weeks of treatment. Increasing clinical evidence indicates that the acute administration of psychedelic agonists of the serotonin 5-HT2A receptor (5-HT2AR), such as psilocybin, to patients with MDD induce fast antidepressant effects, which persist up to five weeks after the treatment.
2024
Mescaline, lysergic acid diethylamide (LSD), and psilocybin are classic serotonergic psychedelics. A valid, direct comparison of the effects of these substances is lacking. The main goal of the present study was to investigate potential pharmacological, physiological and phenomenological differences at psychoactive-equivalent doses of mescaline, LSD, and psilocybin. The present study used a randomized, double-blind, placebo-controlled, cross-over design to compare the acute subjective effects, autonomic effects, and pharmacokinetics of typically used, moderate to high doses of mescaline (300 and 500 mg), LSD (100 µg), and psilocybin (20 mg) in 32 healthy participants. A mescaline dose of 300 mg was used in the first 16 participants and 500 mg was used in the subsequent 16 participants.
2023
Recreational drug use is a significant public health concern in various countries. It is well understood that usage of psychedelics/hallucinogens, such as lysergic acid diethylamide (LSD), ecstasy, phencyclidine (PCP), and psilocybin-containing mushrooms, has increased significantly over the last few decades, particularly in adolescents and young adults, yet the effects of these recreational drugs are poorly understood. Psilocybin has recently been studied as an alternative to traditional antidepressant therapies with potentially benign side effects.
2023
Using a patient-informed regimen, we conducted an exploratory randomized, double-blind, placebo-controlled study to systematically investigate the effects of psilocybin in cluster headache.
2022
Psilocybin (a serotonin 2A, or 5-HT2A, receptor agonist) has shown preliminary efficacy as a treatment for mood and substance use disorders. The current report utilized positron emission tomography (PET) with the selective 5-HT2A receptor inverse agonist radioligand [11C]MDL 100,907 (a.k.a. M100,907) and cortical regions of interest (ROIs) derived from resting-state functional connectivity-based brain parcellations in 4 healthy volunteers (2 females) to determine regional occupancy/target engagement of 5-HT2A receptors after oral administration of a psychoactive dose of psilocybin (10 mg/70 kg).
2022
Hallucinogens are being explored as a potential treatment of psychiatric disorders. Micro dosing of illicitly purchased hallucinogen drugs is on the rise despite conclusive benefits. We aimed to evaluate the prevalence and odds of hopelessness, suicidality, and co-occurring substance use among adolescent hallucinogen users.
2022
Psilocybin has a long history of non-medical use and some seem to infer from this that it has therapeutic utility. Early phase clinical trials with psilocybin are encouraging, but suggest only that larger, multicentre trials are required. These are ongoing but will take many years to complete. Meanwhile, retreat centers offering paid experiences with psilocybin truffles have opened in some countries, often using early phase clinical trial data as a basis for bold, public facing claims. This seems unwise. Early phase trials are not designed for their results to be generalized outside the setting they were undertaken in.
2021
While anecdotal evidence suggests that select 5-hydroxytryptamine 2A (5-HT2A) receptor ligands, including psilocybin, may have long-lasting therapeutic effects after limited dosing in headache disorders, controlled investigations are lacking. In an exploratory double-blind, placebo-controlled, cross-over study, adults with migraine received oral placebo and psilocybin (0.143 mg/kg) in 2 test sessions spaced 2 weeks apart. Subjects maintained headache diaries starting 2 weeks before the first session until 2 weeks after the second session. Physiological and psychological drug effects were monitored during sessions and several follow-up contacts with subjects were carried out to assure safety of study procedures.
2021
A single dose of psilocybin, a psychedelic and serotonin 2A receptor (5-HT2AR) agonist, may be associated with antidepressant effects. The mechanism behind its antidepressive action is unknown but could be linked to increased synaptogenesis and down-regulation of cerebral 5-HT2AR. Here, we investigate if a single psychedelic dose of psilocybin changes synaptic vesicle protein 2A (SV2A) and 5-HT2AR density in the pig brain. Twenty-four awake pigs received either 0.08 mg/kg psilocybin or saline intravenously.
2021